migraine and heart disease in women

Analysis of the Nurses' Health Study found a significant increase in cardiovascular disease in those with migraine (see cad and migraine in women bmj2016 in dropbox, or http://dx.doi.org/10.1136/bmj.i2610 ). details:

--115 541 women aged 25-42 years at baseline and free of angina and cardiovascular disease were followed from the prospective Nurses' Health Study II (from 1989-2011)
--mean age 35; BMI <25 in 68%, 25-30 in 19%; history hypertension 6%, hypercholesterolemia 12%, smoking 14%; no alcohol in 38%, up to 15 g/d in 58%; oral contraceptives in 12%.
--17 531 (15.2%) women reported a physician’s diagnosis of migraine (though no data on presence of aura, migraine frequency, or migraine meds)
--women with migraine were more likely to have hypertension, hypercholesterolemia, family history of MI, BMI>30 or be current smoker
--Results:
    --1329 major cardiovascular disease events occurred, and 223 women died from cardiovascular disease
    --adjusting for potential confounding factors (age, cholesterol, diabetes, hypertension, BMI, smoking, alcohol, physical activity, postmenopausal estrogens, menopausal status, oral contraceptives, aspirin/acetaminophen/NSAID use, and family history MI), migraine was associated with an increased risk for:
            --major cardiovascular disease (hazard ratio1.50, 95% confidence interval 1.33 to 1.69)
            --myocardial infarction (HR 1.39, 1.18 to 1.64)
            --stroke (HR 1.62, 1.37 to 1.92)
            --angina/coronary revascularization procedures (HR 1.73, 1.29 to 2.32)
            --cardiovascular disease mortality (HR 1.37, 1.02 to 1.83)
            ​--associations were similar across subgroups of women, including by age (<50/≥50), smoking status (current/past/never), hypertension (yes/no), postmenopausal hormone therapy (current/not current), and oral contraceptive use (current/not current)

Commentary:
--several studies have found that migraine (specifically migraine with aura) is associated with increased risk of stroke
--the Women's Health Initiative found similar increase in cardiovascular disease (about the same +/- 50% increase as above), but only in those reporting migraine with aura
--several other studies from different countries (Taiwan, Iceland, as well as the American Migraine Prevalence and Prevention Study) have found similar results
--how to explain the association?? unclear. ?increased thrombogenic susceptibility, shared genetic markers, endothelial dysfunction, or inflammation (all have been shown in both migraine and cardiovascular disease). and a recent small study found that the combination of a statin and vitamin D, perhaps through their anti-inflammatory or endothelial effects, decreased the frequency of migraines (for analysis of this study, see prior blog: http://gmodestmedblogs.blogspot.com/2016/01/migraine-prophylaxis-with.html 

--so, it probably makes sense to include migraine (perhaps more so if aura present) in the overall gestalt of cardiovascular risk factors – ie, it would be an added reason to strongly encourage lifestyle changes (smoking, appropriate weight, increasing fruits/veges in diet, exercise) in general, and it might sway me to use statins in those otherwise on the borderline for medical therapy
​ 

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

HDL a negative risk factor? or cholesterol efflux??

Although the data on HDL being protective of atherosclerotic disease is pretty consistent, there are negative studies, and the data on medications which dramatically improve HDL levels (eg, the cholesteryl ester transfer protein --CETP --inhibitors, such as torcetrapib) are clinically disappointing. there have been several explanations for this. for example, some HDL particles are "pro-inflammatory" and elicit an atherosclerotic response (which may be related to apolipoprotein C-III). a new article in NEJM highlights another angle -- that the issue is not the HDL number, but HDL's functionality in the reverse transport of cholesterol, as measured by the cholesterol efflux capacity (see  lipids HDL efflux capacity vs amt NEJM 2014 in dropbox, or  DOI: 10.1056/NEJMoa1409065). This article looks at the Dallas Heart Study, where they measured HDL levels, HDL particle concentrations, and cholesterol efflux capacity in 2924 adults free of cardiovascular disease and followed p
Read more

Drug company shenanigans: narcolepsy drug

I have not done a blog for a long time on drug company shenanigans. So it is my great pleasure to bring up a brand-new drug company approach to garner huge amounts of money (see  https://www.nytimes.com/2023/02/28/business/jazz-narcolepsy-avadel-patents.html?smid=nytcore-ios-share&referringSource=articleShare  ).  Based on an article by  Rebecca Robbins of the New York Times, who has written several articles on drug company excesses   As background, this will be my 42 nd  such blog: for the array, see  https://bucommunitymed.wpengine.com/page/4/?s=drug+company+shenanigans   Th e drug company  approach  this time  to extending  their  patents has a few “interesting” angles: -- this is a medication manufactured by Jazz Pharmaceuticals to treat narcolepsy: there are 2 versions: Xyrem and Xywav (Xywav has less sodium, so is marketed to those who should be on a low sodium diet). These meds are basically derivatives of gammahydroxybutyric acid (GHB)      -- the drug actually has a pretty
Read more

UPDATE: ASCVD risk factor critique

  I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:              -- there is very clear evidence that there are many individual risk factors that are associated with increased risk of a cardiovascu
Read more